Severity
Low
FDA Drug recall · Reported November 29, 2017
Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).
West-Ward Pharmaceuticals Corp. recalled Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01), pa… - a low-severity action.
Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01), pa… was recalled by West-Ward Pharmaceuticals Corp. in November 29, 2017. Reason: Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (rel…. Check the official notice for the remedy. Verify recall #D-0093-2018 with the FDA Drug before acting.
The recall
West-Ward Pharmaceuticals Corp. issued this low-severity FDA Drug recall-Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (rel….
Sourced from official FDA Drug enforcement records. Verify recall #D-0093-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0093-2018) was formally reported on November 29, 2017, with the manufacturer initiating the action on November 6, 2017. It is classified under Low severity (Class III), with a current status of Terminated. West-Ward Pharmaceuticals Corp. is listed as the recalling firm, operating out of Eatontown, NJ. Federal records list the affected scope as 16,157 shelf packs.
The documented reason for this recall is: Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound). Distribution data in the federal record shows the product reached: Nationwide in the USA and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
16,157 shelf packs
Related Recalls
6
5 from same agency
Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01), packaged in 25 x 1 mL Vials per shelf pack (NDC 0641-6145-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.
Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0093-2018 |
| Date reported | November 29, 2017 |
| Date initiated | November 6, 2017 |
| Recalling firm | West-Ward Pharmaceuticals Corp. |
| Firm location | Eatontown, NJ |
| Affected scope | 16,157 shelf packs |
| Distribution | Nationwide in the USA and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 29, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.